Southeast Phase 2 Consortium

SEP2C Overview

The Southeast Phase 2 Consortium (SEP2C) was created in response to NIH N01-CM-57018-16 RFP to conduct Phase II and early clinical trials to evaluate new anti-cancer agents sponsored by the Cancer Therapy Evaluation Program (CTEP). CTEP is an extensive national program for cancer research under the National Cancer Institute (NCI) that focuses on evaluating new anti-cancer agents.

The consortium member institutions are:

  1. The Moffitt Cancer Center at the University of South Florida, Tampa (MCC)
  2. The Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill (LCCC)
  3. The Vanderbilt-Ingram Comprehensive Cancer Center at Vanderbilt University, Nashville (VICCC)
  4. The Winship Cancer Institute at Emory University, Atlanta (WCI)
  5. The Massey Cancer Center at Virginia Commonwealth University, Richmond (VMCC)
    And in 2011
  6. The Cancer Institute of New Jersey (CINJ) was added

The MCC is the coordinating center as well as a participating member.

The consortium recruits subjects from all six participating sites, as well as affiliate sites from member institutions, when necessary. This specific consortium provides significant advantages to CTEP/NCI. Patients enrolled from all sites will mimic the demographic distribution of patients located within the catchment area of each institution.